Nanjing Hicin Pharmaceutical (300584) Stock Overview
Engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
300584 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nanjing Hicin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥51.19 |
| 52 Week High | CN¥81.88 |
| 52 Week Low | CN¥15.54 |
| Beta | 0.39 |
| 1 Month Change | -1.48% |
| 3 Month Change | -9.48% |
| 1 Year Change | 162.24% |
| 3 Year Change | 72.41% |
| 5 Year Change | 181.42% |
| Change since IPO | 379.91% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump
Aug 15
We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve
May 01Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues
Mar 08Shareholder Returns
| 300584 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -6.7% | -0.8% | 1.8% |
| 1Y | 162.2% | 23.4% | 36.0% |
Return vs Industry: 300584 exceeded the CN Pharmaceuticals industry which returned 23.4% over the past year.
Return vs Market: 300584 exceeded the CN Market which returned 36% over the past year.
Price Volatility
| 300584 volatility | |
|---|---|
| 300584 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.5% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 300584's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300584's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 548 | Yuping Cao | www.hicin.cn |
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas.
Nanjing Hicin Pharmaceutical Co., Ltd. Fundamentals Summary
| 300584 fundamental statistics | |
|---|---|
| Market cap | CN¥6.14b |
| Earnings (TTM) | CN¥44.78m |
| Revenue (TTM) | CN¥615.39m |
Is 300584 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300584 income statement (TTM) | |
|---|---|
| Revenue | CN¥615.39m |
| Cost of Revenue | CN¥110.53m |
| Gross Profit | CN¥504.86m |
| Other Expenses | CN¥460.08m |
| Earnings | CN¥44.78m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 25, 2026
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 82.04% |
| Net Profit Margin | 7.28% |
| Debt/Equity Ratio | 27.6% |
How did 300584 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 07:37 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanjing Hicin Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Mengmeng Han | Ping An Securities Co. Ltd. |